Stockscreener 앱 받기
16.12
0.75%
0.12
시간 외 거래:
16.12
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund - Stock Titan
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management - Stock Titan
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Equities Analysts Set Expectations for JANX Q3 Earnings - MarketBeat
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings - MarketBeat
Why (JANX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile - Yahoo Finance
Janus Living Prices Share Offering - marketscreener.com
Janux Therapeutics Inc (JANX) Stock News Today - TradingKey
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - Moomoo
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results - simplywall.st
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside - TradingView
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
Janux Therapeutics earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Janux Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Janux Therapeutics 2Q 2026: Revenue $10.3M, EPS $(0.35) — 10-Q Summary - TradingView
JANX: Clinical pipeline advanced and net loss narrowed, supported by nearly $1B in liquidity - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M - marketscreener.com
JANX: Revenue from BMS collaboration boosted H1 2026 results; net loss narrowed, cash remains strong - TradingView
Janux Therapeutics (NASDAQ: JANX) posts Q2 loss on collaboration revenue - Stock Titan
Janux Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Janux Therapeutics posts $970.9M cash; Q2 net loss $22.0M and revenue $10.3M - TradingView
BRIEF-Janux Therapeutics Q2 Basic EPS USD -0.35 - TradingView
JANX Q2'26 Earnings: revenue estimate is 19.07M USD - TradingView
Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech Gamble with 142% Potential Upside - DirectorsTalk Interviews
Janus Henderson Group PLC Sells 1,154,044 Shares of Janux Therapeutics, Inc. $JANX - MarketBeat
Form 4 Janux Therapeutics Inc For: 31 July By Investing.com - Investing.com Canada
Understanding Momentum Shifts in (JANX) - Stock Traders Daily
Janux Therapeutics, Inc. Revenue Breakdown – NASDAQ:JANX - TradingView
Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Readystate Asset Management LP Has $1.52 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
BlackRock (NYSE: BLK) discloses 6.7% beneficial stake in Janux Therapeutics (JANX) - Stock Titan
Janux Therapeutics Inc (JANX) Balance Sheet - TradingKey
JANX|Janux Therapeutics Inc|Price:15.680|Chg%:+0.350 - TradingKey
Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
JANX|Janux Therapeutics Inc|Price:15.170|Chg%:-0.410 - TradingKey
Janux Therapeutics Inc (JANX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
JANX|Janux Therapeutics Inc|Price:15.635|Chg%:+0.305 - TradingKey
JANX|Janux Therapeutics Inc|Price:15.960|Chg%:+0.640 - TradingKey
Orbimed Advisors LLC Sells 970,826 Shares of Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics Inc (JANX) Income Statement - TradingKey
Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allspring Global Investments Holdings LLC Buys Shares of 168,976 Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics, Inc. (JANX) Stock Price, News, Quote & History - Yahoo! Finance Canada
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership - Moomoo
Janux Therapeutics Inc (JANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Janux Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Barrett Ronald W - Moomoo
Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech Powerhouse with 131.70% Potential Upside - DirectorsTalk Interviews
Avoiding Lag: Real-Time Signals in (JANX) Movement - Stock Traders Daily
Janux Therapeutics (JANX) Gains Momentum: Biotech Stock Rises 2.65% as Buyers Test Key ResistanceIPO Entry Watch - dars.gov.et
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? - MSN
BML Capital Management LLC Purchases Shares of 154,961 Janux Therapeutics, Inc. $JANX - MarketBeat
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
Janux Therapeutics (NASDAQ: JANX) CEO exercises 7,000 options at $4.21, boosts holdings - Stock Titan
Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story? - Yahoo Finance
Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth IndexesWhat's Changed - simplywall.st
0.52%
0.07%
자본화:
|
볼륨(24시간):